Inhibitors of the protein kinase IRAK4 have been developed by others as potential agents in the treatment of cancer and inflammation. A collaboration between Vernalis Research and Asahi Kasei Pharmaceuticals used fragment and structure-based discovery methods to identify novel series of IRAK4 inhibitors that have been assessed in different disease models. The project is available for out-licensing from Asahi Kasei Pharmaceuticals.
« Back to Glossary Index